Initial prostate biopsy: development and internal validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assay.

[1]  E. Steyerberg,et al.  Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculators. , 2012, European urology.

[2]  H. G. van der Poel,et al.  Contemporary role of prostate cancer antigen 3 in the management of prostate cancer. , 2011, European urology.

[3]  A. Tewari,et al.  Prostatic Diseases and Male Voiding Dysfunction Models to Predict Positive Prostate Biopsies Using the Tyrol Screening Study , 2011 .

[4]  M. Kattan,et al.  Development of improved nomogram for prediction of outcome of initial prostate biopsy using readily available clinical information. , 2011, Urology.

[5]  T. D. de Reijke,et al.  Clinical evaluation of the PCA3 assay in guiding initial biopsy decisions. , 2011, The Journal of urology.

[6]  Kim Pettersson,et al.  Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  D Andrew Loblaw,et al.  Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. , 2010, The Journal of urology.

[8]  B. G. Blijenberg,et al.  Screening and prostate-cancer mortality in a randomized European study. , 2009, The New England journal of medicine.

[9]  W. Ellis,et al.  Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram. , 2009, European urology.

[10]  D. Hanbury,et al.  The measurement of psychological distress in men being investigated for the presence of prostate cancer , 2008, Prostate Cancer and Prostatic Diseases.

[11]  Mesut Remzi,et al.  Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. , 2008, European urology.

[12]  Robin J Leach,et al.  Predicting prostate cancer risk through incorporation of prostate cancer gene 3. , 2008, The Journal of urology.

[13]  T. Ichikawa,et al.  Development of a new nomogram for predicting the probability of a positive initial prostate biopsy in Japanese patients with serum PSA levels less than 10 ng/mL , 2008, International journal of urology : official journal of the Japanese Urological Association.

[14]  Seongjoon Koo,et al.  PCA3: a molecular urine assay for predicting prostate biopsy outcome. , 2008, The Journal of urology.

[15]  F. Saad,et al.  Prostate volume and adverse prostate cancer features: fact not artifact. , 2007, European journal of cancer.

[16]  D Andrew Loblaw,et al.  Assessing individual risk for prostate cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  A. Haese*,et al.  Development and external validation of an extended 10-core biopsy nomogram. , 2007, European urology.

[18]  Amy Blase,et al.  PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. , 2007, Urology.

[19]  M. Graefen,et al.  Role of nomograms for prostate cancer in 2007 , 2007, World Journal of Urology.

[20]  D. Katz,et al.  Health perceptions in patients who undergo screening and workup for prostate cancer. , 2007, Urology.

[21]  E. Elkin,et al.  Decision Curve Analysis: A Novel Method for Evaluating Prediction Models , 2006, Medical decision making : an international journal of the Society for Medical Decision Making.

[22]  M. Kattan,et al.  Prostate cancer nomograms: an update. , 2006, European urology.

[23]  M. Kattan,et al.  Nomograms for prostate cancer , 2006, BJU International.

[24]  L. Marks,et al.  APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. , 2006, Clinical chemistry.

[25]  M. Kattan,et al.  Development and validation of a nomogram predicting the outcome of prostate biopsy based on patient age, digital rectal examination and serum prostate specific antigen. , 2005, The Journal of urology.

[26]  G. Lockwood,et al.  Prostate volume is strongest predictor of cancer diagnosis at transrectal ultrasound-guided prostate biopsy with prostate-specific antigen values between 2.0 and 9.0 ng/mL. , 2004, Urology.

[27]  S. Loening,et al.  Re: Hessels D, Klein Gunnewiek JMT, van Oort I, Karthaus HFM, van Leenders GJL, van Balken B, Kiemeney LA, Witjes JA, Schalken JA. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 2003;44:8-16. , 2004, European urology.

[28]  L. Kiemeney,et al.  DD3PCA3-based Molecular Urine Analysis for the Diagnosis of Prostate Cancer , 2003 .

[29]  J. Habbema,et al.  Internal validation of predictive models: efficiency of some procedures for logistic regression analysis. , 2001, Journal of clinical epidemiology.

[30]  M. Mazumdar,et al.  Categorizing a prognostic variable: review of methods, code for easy implementation and applications to decision-making about cancer treatments. , 2000, Statistics in medicine.

[31]  R. Autorino,et al.  Prostate cancer detection in the "grey area" of prostate-specific antigen below 10 ng/ml: head-to-head comparison of the updated PCPT calculator and Chun's nomogram, two risk estimators incorporating prostate cancer antigen 3. , 2011, European urology.

[32]  A. Parwani.  External Validation of Urinary PCA3-Based Nomograms to Individually Predict Prostate Biopsy Outcome , 2011 .

[33]  D L McCullough,et al.  Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate. , 1997, The Journal of urology.